03.20.23 -- Anti-Aging Drugs Need FDA Support, Increased Trial Participation

Though the field of gerotherapeutics is still in its infancy — no drug has yet been approved to prolong health span or lifespan — the need for older adults to participate in clinical trials is expected to increase as these drugs move through the development pipeline.

By focusing on the patient experience, many perceived and real burdens can be designed out of a clinical trial or can be mitigated through technology and strategy.

Spurred by COVID-19, the industry has witnessed an increase in DCT models. Gain insight on how patient-centric approaches to clinical trial travel can increase participation and accelerate research.

In September 2022, there were 6.6 million clinical research jobs posted in the U.S., but only 5.7 million available hires. What accounts for the hiring gap, and how can it be narrowed? Kathi Enderes, SVP, research, and global industry analyst, at The Josh Bersin Company explains why looking outside the field is one way to address worker shortages.

Survivors and their loved ones open up about treatments and challenges they’ve faced while fighting breast cancer. See drug facts on HER2+ and TNBC, and statistics on BRCA, black women, and breast cancer, incidences of breast cancer by age, stage, country, and more.

As technology has advanced, those in charge of trial recruitment and enrollment have been able to employ tools and solutions that allow them to target audiences more likely to fit their studies’ eligibility criteria. However, discover why the practice raises questions and concerns around data privacy. 

The increased demand for hybrid and decentralized approaches to clinical trials has increased the use of digital devices and other tools that will make studies more patient-centric. Sanofi is one of the companies leading the way in getting devices into the hands of patients.

Understand why companies have standardized their operations on the purpose-built, proven platform that gives sites the power to succeed and sponsors the insights to improve performance and compliance.

Phlexglobal's precise, proven methodology delivers a high-quality migration of your trial master file to the destination system, typically just four to six weeks after receiving all documents from the source system.

Florence SiteLink gives sponsors and CROs direct digital access to the network of 10,000 investigator sites across 44 countries managing their eISF on our platform.